The terms of the settlement are confidential and it remains unclear whether generic entry will happen once the main compound patent expires or later due the follow-on patents
The cardiovascular safety profile makes GLP-1 medications particularly attractive for people with diabetes who also have heart disease risk factors
Am J Physiol Endocrinol Metab 292(2):E543-548
Research shows that people who stop GLP-1 medications after losing weight often regain a significant portion of it
Interested in this topic, you can read more in several articles: fat loss vs weight loss, the effects of medically induced weight loss on skeletal muscle, changes in fat-free mass during significant weight loss: a systematic review, and fat-free and skeletal muscle loss with GLP-1 treatments
Symptoms may include facial or throat swelling, difficulty breathing or swallowing, itching or rash, fainting or feeling dizzy, or rapid heartbeat